AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20414671 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical velocity (CV) using two-parameter model (CV(2par))
Number of subjects: 14
Study 20414671 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical velocity (CV) using three-parameter model (CV(3par))
Number of subjects: 14
Study 20414671 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobic distance capacity (ADC) using three-parameter and four-parameter models
Number of subjects: 14
Study 20414671 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal instantaneous velocity (V(max)) in sprint group
Number of subjects: 14
Study 20414671 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal instantaneous velocity (V(max)) using four-parameter model (V(max 4par))
Number of subjects: 14
Study 20414671 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic inertia (tau)
Number of subjects: 14
Study 20414671 — intervention group
Group type: EXPERIMENTAL
Intervention: Model analysis (F test, R(2), R(adjusted)(2))
Number of subjects: 14
Study 20414671 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-parameter model correlation for endurance group
Number of subjects: 14
Study 17873673 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenated glycerol triester (OGT) oral spray (1 or 2 sprays up to 4 times daily)
Number of subjects: 74
Study 17873673 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenated glycerol triester (OGT) oral spray
Number of subjects: 74
Study 17873673 — intervention group
Group type: COMPARATOR
Intervention: Commercially available artificial saliva substitute (ASS)
Number of subjects: 74
Study 15689192 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray administered 120 min after the onset of the attack
Number of subjects: 19
Study 15689192 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray
Number of subjects: 19
Study 15689192 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 19
Study 12236412 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive community treatment (ACT)
Number of subjects: 0
Study 12236412 — intervention group
Group type: COMPARATOR
Intervention: Regular outpatient and inpatient care
Number of subjects: 0
Study 9918893 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg twice daily
Number of subjects: 50
Study 9918893 — intervention group
Group type: COMPARATOR
Intervention: Celiprolol 200 mg daily
Number of subjects: 50
Study 9918893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 7538412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0
Study 7538412 — intervention group
Group type: COMPARATOR
Intervention: Control (no ibuprofen)
Number of subjects: 0
Study 2316840 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nebulisation using a jet nebuliser
Number of subjects: 48
Study 2316840 — intervention group
Group type: COMPARATOR
Intervention: Cricothyroid injection
Number of subjects: 48
Study 2316840 — intervention group
Group type: COMPARATOR
Intervention: Spraying technique
Number of subjects: 48
Study 7309300 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg dihydroxydibutylether (DHBE)
Number of subjects: 0
Study 7309300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31588662 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal root ganglion stimulation (DRG‐S)
Number of subjects: 17
Study 30832739 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Assessment Protocol (GAP)
Number of subjects: 0
Study 30832739 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 30832739 — intervention group
Group type: EXPERIMENTAL
Intervention: GAP
Number of subjects: 0
Study 27577956 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominoplasty with muscle plication
Number of subjects: 125
Study 27577956 — intervention group
Group type: COMPARATOR
Intervention: Abdominoplasty without muscle plication
Number of subjects: 125
Study 27577956 — intervention group
Group type: COMPARATOR
Intervention: Abdominoplasty with vs without muscle plication
Number of subjects: 125
Study 25879810 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching assistant led extracurricular intervention
Number of subjects: 10
Study 24034628 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician prehospital care (including advanced interventions such as rapid sequence intubation and blood transfusion)
Number of subjects: 0
Study 24034628 — intervention group
Group type: COMPARATOR
Intervention: Paramedic care alone
Number of subjects: 0
Study 21249380 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed boat transit (TRAN)
Number of subjects: 24
Study 21249380 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 24
Study 19732415 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management booklet for hip and knee osteoarthritis
Number of subjects: 120
Study 19732415 — intervention group
Group type: COMPARATOR
Intervention: Control booklet
Number of subjects: 120
Study 17708159 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia solution with PA vent and PEEP during CPB
Number of subjects: 142
Study 17708159 — intervention group
Group type: COMPARATOR
Intervention: Control group with cardioplegia entering lung parenchyma
Number of subjects: 142
Study 16282201 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous pain ratings in chronic back pain and chronic postherpetic neuropathy patients
Number of subjects: 0
Study 16282201 — intervention group
Group type: COMPARATOR
Intervention: Ratings of acute thermal painful stimuli or imagined back pain by normal subjects
Number of subjects: 0
Study 16282201 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI brain activity in chronic back pain patients
Number of subjects: 0
Study 12677762 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneokinesis (group A)
Number of subjects: 70
Study 12677762 — intervention group
Group type: COMPARATOR
Intervention: Elastic compression therapy (group B)
Number of subjects: 70
Study 10546696 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-lesson, 6-month classroom curriculum to reduce television, videotape, and video game use
Number of subjects: 192
Study 10546696 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 192
Study 8570798 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical countermeasure (pressing the toes to the floor)
Number of subjects: 40
Study 8570798 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental countermeasure (counting backward by sevens)
Number of subjects: 40
Study 8570798 — intervention group
Group type: COMPARATOR
Intervention: Control group (uninformed subjects)
Number of subjects: 40
Study 1989801 — intervention group
Group type: EXPERIMENTAL
Intervention: IV nicardipine
Number of subjects: 122
Study 1989801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 6679435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 86
Study 6679435 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin plus ampicillin
Number of subjects: 86
Study 6679435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime and carbenicillin during neutropenia
Number of subjects: 86
Study 6679435 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin plus ampicillin and carbenicillin during neutropenia
Number of subjects: 86
Study 6679435 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined initial and cross-over trials
Number of subjects: 86
Study 31908428 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Resistance Training (HI-RT)
Number of subjects: 43
Study 31908428 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 43
Study 29181392 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-hour psychotherapeutic stress management intervention (SMI) based on the Effort‐Reward Imbalance (ERI) model
Number of subjects: 94
Study 29181392 — intervention group
Group type: COMPARATOR
Intervention: External control group (n = 94)
Number of subjects: 94
Study 26058790 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 97
Study 26058790 — intervention group
Group type: COMPARATOR
Intervention: Control (no MRAs)
Number of subjects: 97
Study 23121249 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization schedule
Number of subjects: 26
Study 23121249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 21697300 — intervention group
Group type: EXPERIMENTAL
Intervention: High antioxidant spice blend (14 g) added to a 5060‐kJ (1200 kcal) meal
Number of subjects: 6
Study 21697300 — intervention group
Group type: COMPARATOR
Intervention: Control meal
Number of subjects: 6
Study 19880844 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 4038
Study 19880844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4038
Study 17085985 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin drugs for lowering cardiovascular risk
Number of subjects: 0
Study 15521798 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-word TBR list
Number of subjects: 0
Study 15521798 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-word TBR list
Number of subjects: 0
Study 15521798 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 intervening list
Number of subjects: 0
Study 15521798 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 intervening lists
Number of subjects: 0
Study 15521798 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced rehearsal
Number of subjects: 0
Study 11275921 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 3275
Study 11275921 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 3275
Study 9315315 — intervention group
Group type: EXPERIMENTAL
Intervention: Se-enriched yeast (200 micrograms Se/day)
Number of subjects: 1312
Study 9315315 — intervention group
Group type: COMPARATOR
Intervention: Low-Se yeast placebo
Number of subjects: 1312
Study 8378854 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 125 mg/day and curantyl (150‐225 mg/day) from gestation week 12‐19 till delivery
Number of subjects: 64
Study 8378854 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drugs)
Number of subjects: 64
Study 3005377 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprostene at a maximum dose of 160 ng/kg/min for 8 hours daily for three days.
Number of subjects: 23
Study 3005377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 3005377 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprostene
Number of subjects: 23
Study 29362248 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative medicine-based intervention (three 30 min talks with GPs over 12 months)
Number of subjects: 604
Study 29362248 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative medicine-based intervention
Number of subjects: 604
Study 29362248 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 604
Study 26406216 — intervention group
Group type: EXPERIMENTAL
Intervention: PA lumbar mobilization plus traditional treatment (Ultrasonic and Infra-red)
Number of subjects: 45
Study 26406216 — intervention group
Group type: COMPARATOR
Intervention: Placebo mobilization plus traditional treatment
Number of subjects: 45
Study 26406216 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment only
Number of subjects: 45
Study 25625801 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute strenuous exercise (cycling ergometry)
Number of subjects: 0
Study 25625801 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute bout of intensive exercise
Number of subjects: 0
Study 25625801 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer (6 weeks) or chronic (1 year) increases in physical activity
Number of subjects: 0
Study 25625801 — intervention group
Group type: COMPARATOR
Intervention: Obese subjects
Number of subjects: 0
Study 25625801 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 0
Study 24119487 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused psychological counseling (verum intervention)
Number of subjects: 426
Study 24119487 — intervention group
Group type: COMPARATOR
Intervention: Non-trauma focused counseling (control intervention)
Number of subjects: 426
Study 21413975 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative docosahexaenoic acid (DHA) levels
Number of subjects: 125
Study 21413975 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative arachidonic acid (AA) levels
Number of subjects: 125
Study 21413975 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative total n-3 long-chain polyunsaturated fatty acids (LC-PUFA) levels
Number of subjects: 125
Study 21413975 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 LC-PUFA supplements
Number of subjects: 125
Study 21413975 — intervention group
Group type: EXPERIMENTAL
Intervention: Arachidonic acid (AA) levels
Number of subjects: 125
Study 18315957 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS-AL total hip replacement
Number of subjects: 48
Study 18315957 — intervention group
Group type: COMPARATOR
Intervention: Standard total hip replacement
Number of subjects: 48
Study 16971719 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fingolimod 1.25 mg
Number of subjects: 281
Study 16971719 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fingolimod 5.0 mg
Number of subjects: 281
Study 16971719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 16971719 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous fingolimod
Number of subjects: 281
Study 16971719 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch from placebo to fingolimod
Number of subjects: 281
Study 12656698 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole
Number of subjects: 59
Study 12656698 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg rabeprazole
Number of subjects: 59
Study 12656698 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 59
Study 12564272 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic massage
Number of subjects: 69
Study 12564272 — intervention group
Group type: COMPARATOR
Intervention: Relaxation tape in surgery
Number of subjects: 69
Study 12564272 — intervention group
Group type: COMPARATOR
Intervention: Relaxation tape at home
Number of subjects: 69
Study 10551191 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular telephone contact with a diabetes nurse educator for advice about adjustment of insulin therapy
Number of subjects: 46
Study 10551191 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 46
Study 8723578 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 0
Study 8723578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1662671 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes simplex type I subunit vaccine
Number of subjects: 83
Study 1662671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 6133637 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin, 14.0 +/- 2.4 mg/day in three equal doses
Number of subjects: 6
Study 6133637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6133637 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 6
Study 31014471 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (target blood alcohol concentration = 0.08%; n = 64)
Number of subjects: 128
Study 31014471 — intervention group
Group type: COMPARATOR
Intervention: Nonalcoholic control beverage (n = 64)
Number of subjects: 128
Study 29581078 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 1398
Study 29581078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1398
Study 26150543 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm of a randomized clinical trial of Chinese medicine
Number of subjects: 45
Study 24476781 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (HOX; 30.0% O2)
Number of subjects: 12
Study 24476781 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (NOX; 20.9% O2)
Number of subjects: 12
Study 22335736 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam
Number of subjects: 893
Study 22335736 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lorazepam
Number of subjects: 893
Study 20222930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold atmospheric argon plasma treatment (5 min daily) in addition to standard wound care
Number of subjects: 36
Study 17573449 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise training 3 days/week for 10 weeks
Number of subjects: 15
Study 12410058 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (up to 30 mg per day)
Number of subjects: 9
Study 12410058 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (high-dose)
Number of subjects: 9
Study 9511777 — intervention group
Group type: EXPERIMENTAL
Intervention: Whirlpool bath at 40 degrees C
Number of subjects: 6
Study 7659482 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP
Number of subjects: 2342
Study 7659482 — intervention group
Group type: COMPARATOR
Intervention: DTP
Number of subjects: 2342
Study 2496619 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 12
Study 2496619 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.3 mg)
Number of subjects: 12
Study 2496619 — intervention group
Group type: COMPARATOR
Intervention: Midazolam-Ringer's solution
Number of subjects: 12
Study 2496619 — intervention group
Group type: COMPARATOR
Intervention: Flumazenil alone
Number of subjects: 12
Study 901629 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypolipidaemic therapy
Number of subjects: 14
Study 901629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 29535259 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillating device for respiratory muscle training (8 weeks, 3 times daily)
Number of subjects: 23
Study 28631101 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame bike
Number of subjects: 73
Study 28631101 — intervention group
Group type: COMPARATOR
Intervention: Standard stationary bike
Number of subjects: 73
Study 26316701 — intervention group
Group type: EXPERIMENTAL
Intervention: Test ondansetron oral soluble film formulation
Number of subjects: 10
Study 26316701 — intervention group
Group type: COMPARATOR
Intervention: Reference ondansetron oral soluble film formulation
Number of subjects: 10
Study 23852061 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen inhalation sedation and local anesthesia
Number of subjects: 40
Study 23852061 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia
Number of subjects: 40
Study 21425511 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral interscalene catheter
Number of subjects: 110
Study 21425511 — intervention group
Group type: COMPARATOR
Intervention: Posterior interscalene catheter
Number of subjects: 110
Study 18503607 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide alone
Number of subjects: 8
Study 18503607 — intervention group
Group type: COMPARATOR
Intervention: Glyburide co-administered with Sitagliptin
Number of subjects: 8
Study 16579999 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 36
Study 16579999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 14618045 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (80 mg two times daily for five days starting from the morning of the first postoperative day)
Number of subjects: 207
Study 14618045 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (1.5 g daily for six days starting in the operating room just before cardiopulmonary bypass)
Number of subjects: 207
Study 14618045 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol + Magnesium (both at the same dosages)
Number of subjects: 207
Study 14618045 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antiarrhythmic agents)
Number of subjects: 207
Study 11419424 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy (routine catheterization within 4 to 48 hours)
Number of subjects: 2220
Study 11419424 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy (selectively invasive, catheterization only if evidence of recurrent ischemia)
Number of subjects: 2220
Study 11419424 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 2220
Study 11419424 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 2220
Study 9048454 — intervention group
Group type: EXPERIMENTAL
Intervention: Angulated abutments
Number of subjects: 71
Study 9048454 — intervention group
Group type: COMPARATOR
Intervention: Standard abutments
Number of subjects: 71
Study 8243078 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric multivariate rank test
Number of subjects: 0
Study 8243078 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization tests
Number of subjects: 0
Study 3435920 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX), 40 mg/m2 iv push weekly
Number of subjects: 48
Study 3435920 — intervention group
Group type: COMPARATOR
Intervention: Sequential Methotrexate and 5-fluorouracil (MTX 150 mg/m2 iv for 1 h; 5-FU 600 mg/m2 iv for 2 h; leucovorin rescue 10 mg/m2 iv and orally every 6 h 4 times, repeated every 10 days)
Number of subjects: 48
Study 2239776 — intervention group
Group type: EXPERIMENTAL
Intervention: Skim milk from immunized cows
Number of subjects: 11
Study 2239776 — intervention group
Group type: COMPARATOR
Intervention: Control skim milk (placebo)
Number of subjects: 11
Study 31087685 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent‐Infant Psychotherapy (PIP)
Number of subjects: 61
Study 28453835 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF-containing ART
Number of subjects: 365
Study 28453835 — intervention group
Group type: COMPARATOR
Intervention: ART without TDF
Number of subjects: 365
Study 25950425 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules and normal saline infusion perioperatively (control)
Number of subjects: 80